CRP and esophageal squamous cell carcinoma: We previously found that CAR (C-reactive protein: albumin ratio) and PS (performance status) before nivolumab treatment are useful in predicting long-term survival in patients with recurrent/unresectable advanced ESCC undergoing second-line or later nivolumab treatment [25].